Articles from Galimedix Therapeutics, Inc.

Kensington, MD, USA and Munich/Martinsried, Germany, March 20, 2026 (GLOBE NEWSWIRE) --

Kensington, MD, USA and Munich/Martinsried, Germany, March 12, 2026 (GLOBE NEWSWIRE) -- Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation

Kensington, MD, USA and Munich/Martinsried, Germany, March 05, 2026 (GLOBE NEWSWIRE) -- Galimedix Therapeutics to present promising pre-clinical data with next generation oral amyloid beta aggregation modulator at AD/PD™ 2026 Conference

Kensington, MD, USA and Munich/Martinsried, Germany, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025